Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled study

Neurology

Volumn 83, Issue 9, 2014, Pages 826-833

  Papay, Kimberly ^a   Xie, Sharon X ^a   Stern, Matthew ^a   Hurtig, Howard ^a   Siderowf, Andrew ^b   Duda, John E ^a,c   Minger, James ^a   Weintraub, Daniel ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b AVID RADIOPHARMACEUTICALS   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; NALTREXONE; PLACEBO; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; BARRATT IMPULSIVENESS SCALE; BECK HOPELESSNESS SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; GERIATRIC DEPRESSION SCALE; HUMAN; IMPULSE CONTROL DISORDER; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; NAUSEA; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE FOR IMPULSIVE COMPULSIVE DISORDERS IN PARKINSON DISEASE RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; COMPLICATION; IMPULSE CONTROL DISORDERS;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PARKINSON DISEASE;

EID: 84920928928     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000729     Document Type: Article

References (39)

1. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007;64:1089-1096.
2. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-595.
3. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: A multicenter case-control study. Ann Neurol 2011;69:986-996.
4. Phu A, Xu Z, Brakoulias V, et al. Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients. J Clin Neurosci 2014;21:63-66.
5. Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne E, Burns A. Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry 2012;27:160-166.
6. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008;23:75-80.
7. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63.
8. Smeding HMM, Goudriaan AE, Foncke EMJ, Schuurman PR, Speelman JD, Schmand B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007; 78:517-519.
9. Thomas A, Bonnani L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010;68:400-404.
10. Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010;68: 963-968.
11. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-880.
12. Martin WR, Jasinski D, Mansky P. Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 1973;23:784-789.
13. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001;49: 914-921.
14. Grant JE. Three cases of compulsive buying treated with naltrexone. Int J Psychiatry Clin Pract 2003;7:223-225.
15. Grant JE, Kim SW. A case of kleptomania and compulsive sexual behavior treated with naltrexone. Ann Clin Psychiatry 2001;13:229-231.
16. Neumeister A, Winkler A, Wöber-Bingöl C. Addition of naltrexone to fluoxetine in the treatment of binge eating disorder. Am J Psychiatry 1999;156:797. Letter.
17. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994;9:437-440.
18. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999;56:33-39.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
20. Grant JE, Steinberg MA, Kim SW, Rounsaville BJ, Potenza MN. Preliminary validity and reliability testing of a structured clinical interview for pathological gambling. Psychiatry Res 2004;128:79-88.
21. McElroy SL, Keck PE, Pope HG, Smith JM, Strakowski SM. Compulsive buying: A report of 20 cases. J Clin Psychiatry 1994;55:242-248.
22. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254-1257.
23. Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord 2012;27:242-247.
24. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53: 695-699.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. DHEW Publication No. (ADM) 76-338. Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
26. Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer's disease. Am J Geriatr Psychiatry 2010;18:136-145.
27. Porsteinsson A, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA 2014;311:682-691.
28. Fahn S, Elton RL; the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163.
29. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: A survey by the Canadian Movement Disorders Group. JAMA 2005;287:455-463.
30. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson's disease. Neurology 2010;75:448-455.
31. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: A generalized estimating equation approach. Biometrics 1988;44:1049-1060.
32. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982;38:963-997.
33. Davis C. The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol 1976;104:493-498.
34. Howard R, Phillips P, Johnson T, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry 2011;26:812-817.
35. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-1847.
36. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007;64:212-216.
37. Croop RS, Faulkner EB, Labriola DF; Naltrexone Usage Study Group. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry 1997;54:1130-1135.
38. Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013;80:792-799.
39. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study. Biol Psychiatry 2007;62:652-657.